Revolution Medicines presented expanded Phase 3 results for daraxonrasib at ASCO, showing markedly longer survival versus standard chemotherapy in metastatic pancreatic cancer driven by KRAS G12 mutations. In the full trial population, daraxonrasib extended median survival to 13.2 months compared with 6.6 months for chemotherapy, with similar outcomes for progression-free measures. For patients with RAS G12 mutations, median overall survival and tumor control measures roughly doubled compared with chemotherapy comparators, according to the updated analysis presented at the meeting and published alongside it. Investigators also highlighted rapid improvements in patient-reported pain and tumor markers following treatment initiation. The data—particularly the survival benchmark reported as unprecedented for any pancreatic cancer patient group in a clinical trial—positions daraxonrasib as a potential practice-changing second-line option, pending the full regulatory and clinical context that will follow.